Gland Pharma Limited – FDA 483, Aug 25, 2022
Gland Pharma Limited, a drug-device combination manufacturer in Hyderabad, India, received a Form FDA 483 for deficiencies in its quality system. The inspection revealed that the firm had not established adequate procedures for design control, specifically failing to define design input requirements and ensure scientific justification for its Icatibant Injection product. Furthermore, the company had not fully implemented its quality risk management procedure, leading to an incomplete identification of potential faults and hazards.
ID · cbd5ee58-0d35-4dc8-a3c5-c1f424b4f63a
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.